Land available for development

Illustrative plan of Phase 2 expansion land with indicative building layout.

Phase 2 plans

Ideas, new treatments and devices are being developed at Cambridge Biomedical Campus to meet the demands of the world’s healthcare challenges. We succeed because of the strength of our ecosystem which allows ideas to develop and flourish. We have the physical space to accommodate new and expanding companies and the international connections to be the global hub for content and research. Having nurtured companies, developed a highly skilled workforce and encouraged outside investment in Cambridge, the Campus is ready to create and welcome the next generation of companies. Construction will start in 2023 of a multi occupancy laboratory/office building of 100,000 sq ft. Alternatively, bespoke single occupancy buildings can be developed to suit occupier needs. To discuss the development opportunities in Phase 2 of the Cambridge Biomedical Campus, please contact one of our agents at the bottom of the page. 6 reasons to locate to CBC.

In 2009, planning permission covering 70 acres became the catalyst for the first phase expansion of the campus, raising its status into a truly internationally competing academic health science centre.

The ensuing years have seen new committed development hit 1,800,000 sq ft gross (167,224 sq m).

With the Phase 1 expansion land now fully committed, the development of the Phase 2 expansion land is now underway. With a landscape-led approach, this next stage will thread a series of new high specification office and laboratory buildings between a string of green, shared spaces, enhanced by public art, to promote formal and informal meetings.

The total Phase 2 floor area available for development is 807,000 sq ft (75,000 sq m) gross, comprising 636,000 sq ft (59,000 sq m) of commercial floor space, including Abcam, and 171,000 sf ft gross (15,900 sq m) of clinical floor space.

Anchoring the Phase 2 expansion land is the Abcam headquarters. The next building to be constructed, adjacent to Abcam, will provide a new, speculatively developed lab/office building of 100,000 sq ft net, over 5 storeys (9290 sq m), scheduled to be available in 2023.

The developer of the expansion of the Cambridge Biomedical Campus is

Prologis UK

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of September 30, 2021, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 994 million square feet (92 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.